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• Apoptoals and Early Necrosis In Perltransplant 
Ischemlc Injury andAcuta Allogralt Rejection In 
Human Heart ~ansp lant  Recipients 
J,D, Day, R, ORe, U, N~raslmhnn, S, Oopnt, M,T, Day, EK, K~spor, 
C,.L, Chon, ~,J, Cinn, A,L, Rebedson, R,H, Hruben, SfanfoM Un/vemily 
Hob#/fat, Stanford, CA: The Jottn~ Hopktn,~ Medical Insfiluftens, Eta/timers, 
MC~ USA 
~,~ckground; Coil cloath may ouour by apopto~ or noorosis, Apoptosls is a 
phy~lolOglo process for disposing Dells through orderly soil deotruoflon, while 
no~rosls results from cytolytlo oh~ngos following Doll miss/ WQ nssos.~od 
their p~ttom aed extonl ~n m~,l~tlple samp~ ~a fre~~ ;~9 p.',ient ,~ 
M~lhpd~; Apoptosio was doto(;tod by in sih4 er~d labeling and n(l~l~ar 
cl~mm~ftn ~lalntng and neorosts tmmunohlstochomt~dly using a ooniug=Ued 
myosin light chain monoclonal ~ntibody, Accompanying tnflsmmalery infil. 
trains were Id~nttflod by tmmgnop, rexidasa staining of lymphncvle subsets 
Rosult~ were oompared with clinical doln ~nd re~dlnn hem~toxylin.~esln 
evaluation of ondomyocnrdh~l btopslns, 
RP,qUII~: Apoptosta was Identified at tbe perlphoq/of the isel~amlc to0i 
in 75% of the biopsi¢ls that showod peri(ransplant lachemic mltlry by Iigl~t 
mtoros~opy, whllo ~mmt!noh(~tochnmloal slolnlng for myosin light ohain leNly 
nocrests) was obsontod within the cores of ~11 lschomic loci, Apoptottc my. 
DO/los w~re observed In 90% el the blopsteS which showed aouto rejection 
and immunohtstochomlcnl staining for myosin light chain was obeowod in 
86% el those btopstea Endy myocyto necresls waa dotoctod in 70% Of the 
bl0psi0S ovakmted without necrosis by reutlne I~lslologle grading (Grade tA 
• relo¢tlon), 
Cor~lusipn: Slgnllieant myncyto cell death In the term el both apoptoscs 
and eady nacrests ocours in porttransplant ischemic Injury and ;n acute silo. 
grell mloctlon, The idnnllticOtlo r' nl Irrevor~Ibln i troeolMar myosin release 
by the use of monoclonal myosin light chain antibodies In tissue sections 
proved to be a sensitive techmque for detecting the earliest stages el local 
m,/ocyle ~ms(s. 
"~ of Mild In Steroid-free The Meaning Rejection 
Heart Transplant Recipients 
JA. Kobeshlgawa, K. Einhom, TK. Re, JD, Cassom, J,D. Morigocht, 
MA Hamilton, A Hope, N Kawafa, H Lake. Umverslh, of Cahtornia. Lo.~ 
An.c/elo.,~, CA, USA 
It has boon reported that todd reiection (rsi) tn heart transplant patients 
progresses to a more severe form of roj in 10-20% of follow-up blopst0s. 
Many patients are now being weaned from corttcostoretds and it has not 
been established whether mild rej has a similar outcome in these patients, 
To assess the natural htstont of untreated mild (ISHLT 1A, 1 B) and untreated 
focal moderato (ISHLT 2) rej in patients off corticosloreids, we reviewed 
106 patients transplanted between 4•86 and 9/95 with an average time from 
transplant lo corticosteretd-freo tmmunosuppmaslon f 20 t 10 months. In 
those patients, there wore 126 episodes el untreated mild and local moderate 
rei with outcemos demonstrated in the table. 
Episodes Nexl Biopsy 
N CIoorod Pe~'SisIed Pro0ros~od 
1A 91 67 (74%) 2~ (24%) 2 (2=0) 
113 14 I '7%) 10 (71%~ 3 (220.) 
2 2.1 15 (71"o) 4 (19%1 2 (10%) 
Moderate rei was eventually seen in those "persisted" rei episodes in 
the following incidence: 1/22 grade 1A episodes, 1/10 grade 1B episodes, 
and 0/5 grade 2 episodes. Therefore, in patients with 1B rej, a total of 4/13 
episodes (31%) progressed to moderate rei which required anti-relection 
therapy. During the time ot fhts study, there were 198 abnormal hiopsies 
(includir,g all Desisted reis) out ol a tolal of 845 biopsies performed (23%). 
Conclusion: Cardiac transplant patients who are on steroid-tree immune- 
suppression should have careful fogow-up if their ondomyocardial biopsies 
demonstrate 1B rejection. ISHLT 1A and 2 biopsy gradss appear to have 
lower risk for progression to moderate rejection. Surveillance biopsies may 
be necessary to detect rejection in these patients maintained off corlicos- 
toroids. 
• Predictive Modal to Coronary Asso~s Risk for 
Artery Disease attd Graft Fellure In Cardiac 
Alfogrsft Recipients: An Immunocyfochsmlcel 
Study 
C,A, Labarrem, D.R, Nelson, D.E, Plffs, P,C, Klrlin, H, Halbrook, C/arian 
Health (Methodist, Indiana Uniwrsity, Riley Hospitals), Indsanapolis, 
Indiana, USA 
B~ckgmund: We dev~lopsd a model for endy idenliticaflon el ro¢ipient~ 
wile subsequently dnvelep transplant.associated coronary adory disease 
(Tx,CAO) and graft failure, 
Me.rhode: Serial blopslos obtained from 121 cnrdiao allograMs (55 :t 0,1 
blopsioalpntlent) during the fi~t three months post.tron~plnnt wnm ovatu~t~l 
for deposition of microvascular libnn, depletion of ad~olsr tissue pl~smino- 
pen activator, pmsonoo el adorinl/aderieIRr endotholiat activation roarkere 
ICAM.t and HLA.DR, and changes in vasoular antithrombin, An immunoo/. 
tochemlcal risk acorn fIRS) was studied for fmsO¢ieltion with subseqtrent grail 
foiltlm and develepmonf ~lnd progression el Tx-CAD detail, led using senal 
corena~ angionmm,~ 13,2 t 0,PJpationl), 
Rosvlls: AIIoqrefts wilh low IRS (scorn ~ 0) developed significantly less 
TxCAD (p - O,qOl) lhan allegretto with moderato {score = 0.5-,~3.0) or 
hii]h (score = 3,fi~4.0) IRS The disease progressed in P~,, tP~ and 44% 
of allegretto with low, moderate and high IRS, respectively lP - 0.001). 
Allegretto with low IRS h~d sigo(ticantly less gram failure (p ~ O001) than 
allegretto with moderate r high IRS. 
Cor~t¢tsl(ln: Early (~hangos in the micrevasculatum am assoCiated with 
impending Tx.CAD and gram failure in cardiac allogratt reOpmnts. 
~ Oetectlon AntI-HLA Antibody byFIow of 
Cyfomstry In Patients Wllh s Left Ventr!cular 
Assist  Oevlce Is Asso©!Mlld With Early Relm:tion 
Following Heart Transplantation 
D. OeNolrio, F,-J. Morales, M. Kamoun, J. Koams, C. Dorezinsky. 
OR, Rosengard, M,A Ackor, E. Loh. Unlversl~" nf Pennsylvania/-k~ffh 
System, Phllad~l,)hla, PA, USA 
Patients squiring a tell vontncular assist deride (LVAO) as a bridge 10 heart 
transplantation (HT) olten have elevated levels el panel reactive ant~bodms 
(PRA). The clinical significance of anti-HLA antibodies detected by flow 
cytomotn/in PRA negative patients remains unclear. Eighteen patients who 
underwent LVAD placement as a successful badge to HT had simultaneous 
flow cytomelry and standard anti.human globulin complement Dependent 
cytotoxicity (AHG-CDC) assays portormed to detect anti.HLA antibodies. A 
positive flow result was defined by a ItuoresCont ratio of ;3:1 vs controls. 
Two patients with a pas~tivo PRA and one pattent with panoperative death 
seconda~, to relractory pulmona~t hypertension were excluded. The study 
population (n = 15) had a moan ago of 44 t 15 yrs, 88",, were male. and 
the mean duration of LVAD support was 94 t 53 days. In patients with 
anti-HLA antibodies detected by flow cytometnt (n = 6). univa.ato analysis 
demonstrated mere mederate-sevore rejection episodes (ISHLT ~3A) at 2 
months (0.83 ~. 035 vs 0: p = 0.04) and a trend towards decreased time 
to first releclion (61 * 17 days vS 225 ~ 62 days: p = 0.06). No diNerences 
in donor recipient HLA mismatch or Kaplan-Meier survival at one year were 
observed 
Conclusions: Despite a negative PRA. LVAD patients with anti-HLA an- 
tibodies detected by flow cytometn/have a greater incidence ot moderate- 
severe reiection in the hrst 2 months tollowing HT. Flow cytometn/may be a 
useful clinical tool in screening PRA negative LVAD patients prior to trans- 
plantation. Patients with positive flow cytometry may require more intensive 
immunosupprossion i the early post-HT penod. 
• Effective Long-term Methotrexate Therapy for 
Acute AIIograft Rejection After Heart 
Transplantation 
G.M. Mullen, M.A. Silver, C.E. Lawless, J. Mendez, P.C. Barath, 
K. Malinowska, B.A. Pisani, J.A. Robinson. Loyola University of Chicago. 
Heart Transplant Program, Maywood, Illinois. USA 
In spite el progress in im,'nunosuppressive therapy, acute allograft rejection 
(AAR) still rereains a major cause el death and allogralt dysfunction alter heart 
transplantation (HT). Standard "triple-dnJg* immunolherapy (cyclosporine, 
azalhioprine and predntsoile) is effective against most, but not all AAR. 
Other adlunctive agents such as methotrexato (MTX) have been used to 
decrease frequency and severity of AAR, but its long-term effectiveness is 
unknown. We retrospectively reviewed 366 HT recipients of whom 34 had 
received MTX for AAR. We then divided patients into two groups based on 
AAR grade using a weighed numerical scale, Group I (<3) and Group !1 (-3). 
